liver cancer
Conditions
Interventions
experimental group:Camrelizumab 200mg d1/q21, Apatin 250mg po qd, PEG-rhG-CSF 6mg q21
control group:Placebo subcutaneous injection
Sponsors
Department of Oncology, the Eighth People's Hospital of Jinan
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years; 2. Histologically confirmed diagnosis of unresectable or metastatic HCC; 3. Completed CPS score detection, who are classified as below stage IIIB of chinalivercancerstaging (CNLC), who are treated or progressing or are not resistant to first-line targeted therapy; 4. According to the imRECIST standard, there is at least one diameter line that can be accurately measured; 5. The performance status of the eastern cancer cooperation group (ECOG) is 0 or 1; 6. Expected life is more than 12 weeks; 7. Child-Pugh A/B.
Exclusion criteria
Exclusion criteria: 1. Patients with cholangiocarcinoma, sarcomatoid liver cancer, mixed cell carcinoma, fibrous lamellar cell carcinoma, or other cancers for 5 years; 2. Patients with moderate or severe ascites and clinical symptoms (i.e. patients requiring therapeutic puncture and drainage), or uncontrolled pleural effusion or pericardial effusion; 3. Patients previously treated with PD-1 or PD-L1 inhibitors or apatinib; 4. Patients with severe gastrointestinal bleeding, gastrointestinal perforation or intestinal obstruction or unable to swallow within 6 months before enrollment; 5. Patients with severe infection; 6. Patients with a history of embolism, cerebral infarction or pulmonary infarction; 7. Patients with uncontrolled or unstable angina pectoris, uncontrolled hypertension, arrhythmia, cardiac insufficiency, congestive heart failure, or myocardial infarction less than 6 months after treatment; 8. Patients with interstitial pneumonia, interstitial lung disease, autoimmune diseases, congenital or acquired immunodeficiency; 9. Have a history of severe drug allergy to single drug or targeted therapy; 10. A woman who is pregnant or planning to become pregnant, or a man whose partner is considering becoming pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival; | — |
Countries
China
Contacts
Public ContactZhang Weike
The Eighth People's Hospital of Jinan
Outcome results
None listed